Chris Klomp is the Centers for Medicare and Medicaid Services (CMS) Medicare Director as of the 2026 rollout of the Medicare GLP-1 Bridge demonstration program. Klomp led the CMS launch call on Tuesday June 30, 2026 outlining the operational architecture of the Bridge (Humana as central processor for prior authorization and claims adjudication; 72-hour PA turnaround target; Bridge-specific BIN 028918 and PCN MEDDGLP1BR pharmacy billing identifiers) and set the participation expectation at 'single-digit millions' at first, with volume ramping through Q3 and Q4 2026.
Klomp's forecast anchors the KFF cost-projection analysis published this week: at 10% participation of the 3.8 million eligible Part D enrollees, Medicare pays $1.3 billion over the 18-month demonstration; at 25% participation, $3.3 billion; at 50%, $6.7 billion; at 75%, $10 billion. Klomp's 'single-digit millions' framing suggests the middle of the KFF range as the operational baseline the agency is planning around. Becker's Payer flagged that CMS could not confirm cost or enrollment projections on the launch call, leaving analyst modeling dependent on Klomp's informal expectations rather than a formal CMS forecast.
Klomp will also oversee the transition from the Bridge to the broader BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) launching January 1, 2027 in Medicare Part D, with the Bridge ending December 31, 2027 and beneficiaries transitioning to BALANCE. Stories tagged here cover Klomp statements, CMS operational updates, and the broader Medicare obesity-coverage policy track. See [[medicare-glp-1-bridge]], [[balance-model]], and [[cms]] for adjacent threads.
KFF (formerly Kaiser Family Foundation) published cost-projection detail on the Medicare GLP-1 Bridge demonstration this week that goes beyond the 3.8 million eligibility headline into the fiscal outlay Medicare actually books. The math: Medicare's net drug payment runs $195 per beneficiary per month ($245 negotiated net drug price minus the $50 patient copay). At 10% participation of the 3.8 million eligible Part D enrollees, monthly refills across the 18-month program cost Medicare roughly $1.3 billion; at 25% participation, $3.3 billion; at 50% participation, $6.7 billion; at 75% participation, $10 billion. CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first with volume ramping through Q3 and Q4 2026, suggesting the middle of the KFF range as the most probable outcome. The Bridge operates outside the standard Part D risk pool, meaning Part D plan sponsors do not carry actuarial risk for these drugs; beneficiary spending under the Bridge does not count toward the Part D $2,100 annual out-of-pocket cap for 2026. The cost-projection frame is the piece analysts and Congressional staff will use to judge Bridge success over the next 18 months.
Day 2 of the Medicare GLP-1 Bridge demonstration ran through Thursday July 2, 2026 as the first prior-authorization submissions filed on Wednesday July 1 began flowing through Humana as central processor. CMS targets 72-hour turnaround on PA decisions, which puts the earliest Bridge-covered first fills at the pharmacy counter around Thursday July 3 to Friday July 4 for prescriptions submitted Wednesday. The wider first-fill wave is expected the week of July 6 as pharmacies complete Bridge-specific billing system setup using the Bridge BIN 028918 and PCN MEDDGLP1BR identifiers, and as prescribers gain familiarity with the eligibility-attestation workflow (BMI at start of GLP-1 therapy, absence of type 2 diabetes / moderate-to-severe OSA / MASH which would route to standard Part D instead). Humana's parallel role as the Limited Income Newly Eligible Transition (LI NET) program administrator provides operational infrastructure that CMS Medicare Director Chris Klomp cited on the Tuesday launch call as the reason the central-processor model can scale from Day 1 without a ramp-up window. Independent operational tracking through July will indicate whether the 72-hour PA target holds as volume builds.
KFF (formerly Kaiser Family Foundation) published an analysis estimating 3.8 million Medicare beneficiaries could have qualified for the Medicare GLP-1 Bridge in 2023 based on the three BMI-and-comorbidity eligibility tiers (BMI ≥35 no paired condition; BMI ≥30 with heart failure, uncontrolled hypertension, or chronic kidney disease; BMI ≥27 with pre-diabetes, prior MI, prior stroke, or symptomatic peripheral artery disease). CMS Medicare Director Chris Klomp told reporters on the launch call that the agency expects participation to run in the 'single-digit millions' at first, with volume ramping through Q3 and Q4 2026 as prescriber and pharmacy familiarity grows. Centene confirmed participation in the Bridge program despite the parallel delay in its Medicare Advantage pilot. The Bridge operates outside standard Part D risk pools; Part D plan sponsors do not carry risk for eligible GLP-1 drugs under the Bridge. Net drug pricing runs $245/month with CMS covering $195 and the patient paying the $50 copay.